About Omkar Pharmachem Limited
Data last updated:
Omkar Pharmachem Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 31 March 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L93000GJ1995PLC025276. Its GSTIN is 24AAACO1845N1ZC (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 532167.
The company has an authorised share capital of ₹10.5 Cr and a paid-up capital of ₹10.08 Cr. It is led by directors including Bhawani Shankar Goyal (Managing Director) and Parminder Sharma.
Its last annual general meeting (AGM) was held on 24 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 310 Wall Street – 1 Near Gujarat College Cross Road Ellisbr, Idge, Ahmedabad, Gujarat, India – 380006.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹47 Lakh, a decline of 13% compared to the previous year. For the same year it recorded a net profit of ₹14 Lakh (net margin 29.8%) and EBITDA of ₹17 Lakh (EBITDA margin 36.2%). The net worth stands at ₹36.64 Cr (up 288.5% YoY). Total assets are valued at ₹36.64 Cr (up 283.7% YoY).
As per MCA filings, the company has satisfied charges of ₹10.89 Lakh on record. Court records list 2 cases involving the company, including 2 filed against it.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website omkarpharmachem.co.in.
Company details
CIN history
Omkar Pharmachem has one previous CIN (Corporate Identification Number): L24231GJ1995PLC025276. The current CIN is L93000GJ1995PLC025276, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L93000GJ1995PLC025276 | Current |
| L24231GJ1995PLC025276 | Previous |
Contact details
Omkar Pharmachem Limited's registered office is in Ahmedabad, Gujarat. Its website is omkarpharmachem.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address310 Wall Street – 1 Near Gujarat College Cross Road Ellisbr, Idge, Ahmedabad, Gujarat, India – 380006
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Omkar Pharmachem Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Omkar Pharmachem is support service to organizations. In detail, this covers other support services to organizations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| N | Support service to Organizations | N7 | Other support services to organizations |
To see the full business activity and turnover split of Omkar Pharmachem Limited, buy the company report.
Financials of Omkar Pharmachem Limited
FY 2025-26 filings availableOmkar Pharmachem Limited reported revenue of ₹47 Lakh (down 13% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.47 | 0.54 | 0.54 | 0.54 | 0.54 | 0.27 | 0.05 |
| Revenue growth | -13.0% | 0.0% | 0.0% | 0.0% | +100.0% | +440.0% | - |
| EBITDA | 0.17 | 0.30 | 0.29 | 0.31 | 0.28 | 0.03 | (0.19) |
| EBITDA margin | +36.2% | +55.6% | +53.7% | +57.4% | +51.9% | +11.1% | -380.0% |
| Profit before tax | 0.18 | 0.27 | 0.26 | 0.26 | 0.22 | (0.03) | (0.24) |
| Net profit | 0.14 | 0.20 | 0.20 | 0.19 | 0.19 | 0.23 | (0.24) |
| Net profit margin | +29.8% | +37.0% | +37.0% | +35.2% | +35.2% | +85.2% | -480.0% |
| EPS (₹) | 0.12 | 0.20 | 0.19 | 0.20 | 0.18 | 0.22 | (0.26) |
| Balance sheet | |||||||
| Total assets | 36.64 | 9.55 | 9.54 | 9.67 | 9.78 | 9.57 | 9.31 |
| Net worth | 36.64 | 9.43 | 9.23 | 9.04 | 8.84 | 8.66 | 8.44 |
| Total debt | 0.00 | 0.12 | 0.30 | 0.62 | 0.93 | 0.90 | 0.87 |
| Cash & bank | 0.22 | 0.11 | 0.07 | 0.13 | 0.21 | 0.04 | 0.04 |
| Net working capital | 0.25 | 0.22 | 0.13 | 0.20 | 0.24 | 0.01 | 0.01 |
| Cash flow | |||||||
| Cash from operations | 0.23 | 0.24 | 0.30 | 0.28 | 0.20 | 0.02 | (0.21) |
| Cash from investing | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | 0.00 |
| Cash from financing | (0.12) | (0.20) | (0.35) | (0.35) | (0.03) | (0.02) | 0.24 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.09 | 0.09 | 0.11 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 |
| Revenue growth (YoY) | -35.7% | -35.7% | -21.4% | 0.0% | 0.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.10 | 0.07 | 0.06 | 0.07 | 0.10 | 0.07 | 0.05 | 0.05 |
| EBITDA | (0.01) | 0.02 | 0.05 | 0.07 | 0.04 | 0.07 | 0.09 | 0.09 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Profit before tax | (0.01) | 0.02 | 0.05 | 0.07 | 0.04 | 0.05 | 0.09 | 0.09 |
| Tax | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.07 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.09 | 0.09 | 0.11 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 |
| Revenue growth (YoY) | -35.7% | -35.7% | -21.4% | 0.0% | 0.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.10 | 0.07 | 0.06 | 0.07 | 0.10 | 0.07 | 0.05 | 0.05 |
| EBITDA | (0.01) | 0.02 | 0.05 | 0.07 | 0.04 | 0.07 | 0.09 | 0.09 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Profit before tax | (0.01) | 0.02 | 0.05 | 0.07 | 0.04 | 0.05 | 0.09 | 0.09 |
| Tax | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.07 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.47 | 0.54 | 0.54 | 0.54 | 0.54 | 0.27 | 0.05 |
| Revenue growth | -13.0% | 0.0% | 0.0% | 0.0% | +100.0% | +440.0% | - |
| Other income | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.30 | 0.24 | 0.25 | 0.23 | 0.26 | 0.24 | 0.24 |
| Employee cost | 0.21 | 0.16 | 0.16 | 0.14 | 0.17 | 0.15 | 0.15 |
| EBITDA | 0.17 | 0.30 | 0.29 | 0.31 | 0.28 | 0.03 | (0.19) |
| EBITDA margin | +36.2% | +55.6% | +53.7% | +57.4% | +51.9% | +11.1% | -380.0% |
| Depreciation | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.02 | 0.03 | 0.05 | 0.06 | 0.06 | 0.05 |
| Profit before tax | 0.18 | 0.27 | 0.26 | 0.26 | 0.22 | (0.03) | (0.24) |
| Tax | 0.04 | 0.07 | 0.06 | 0.07 | 0.03 | (0.26) | 0.00 |
| Net profit | 0.14 | 0.20 | 0.20 | 0.19 | 0.19 | 0.23 | (0.24) |
| Net profit margin | +29.8% | +37.0% | +37.0% | +35.2% | +35.2% | +85.2% | -480.0% |
| EPS (₹) | 0.12 | 0.20 | 0.19 | 0.20 | 0.18 | 0.22 | (0.26) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 |
| Reserves & surplus | 26.56 | (0.65) | (0.85) | (1.04) | (1.24) | (1.42) | (1.64) |
| Shareholders' funds (net worth) | 36.64 | 9.43 | 9.23 | 9.04 | 8.84 | 8.66 | 8.44 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.12 | 0.30 | 0.62 | 0.93 | 0.90 | 0.87 |
| Total debt | 0.00 | 0.12 | 0.30 | 0.62 | 0.93 | 0.90 | 0.87 |
| Total liabilities | 36.64 | 9.55 | 9.54 | 9.67 | 9.78 | 9.57 | 9.31 |
| Assets | |||||||
| Gross block | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 |
| Net block | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 36.38 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 0.03 | 0.10 | 0.05 | 0.13 | 0.08 | 0.03 | 0.02 |
| Cash & bank balances | 0.22 | 0.11 | 0.07 | 0.13 | 0.21 | 0.04 | 0.04 |
| Loans & advances | 0.05 | 0.06 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total current assets | 0.30 | 0.27 | 0.19 | 0.26 | 0.29 | 0.07 | 0.06 |
| Total current liabilities | 0.05 | 0.05 | 0.06 | 0.06 | 0.05 | 0.06 | 0.05 |
| Net working capital | 0.25 | 0.22 | 0.13 | 0.20 | 0.24 | 0.01 | 0.01 |
| Total assets | 36.64 | 9.55 | 9.54 | 9.67 | 9.78 | 9.57 | 9.31 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.11 | 0.07 | 0.13 | 0.21 | 0.04 | 0.04 | 0.02 |
| Net cash from operating activities | 0.23 | 0.24 | 0.30 | 0.28 | 0.20 | 0.02 | (0.21) |
| Net cash from investing activities | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | 0.00 |
| Net cash from financing activities | (0.12) | (0.20) | (0.35) | (0.35) | (0.03) | (0.02) | 0.24 |
| Net change in cash | 0.11 | 0.04 | (0.06) | (0.08) | 0.17 | 0.00 | 0.02 |
| Closing cash | 0.22 | 0.11 | 0.07 | 0.13 | 0.21 | 0.04 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -13.0% | 0.0% | 0.0% | 0.0% | +100.0% | +440.0% | - |
| EBITDA growth | -43.3% | +3.5% | -6.5% | +10.7% | +833.3% | +115.8% | - |
| PBT growth | -33.3% | +3.9% | 0.0% | +18.2% | +9998.0% | +87.5% | +42.9% |
| Net income growth | -30.0% | 0.0% | +5.3% | 0.0% | -17.4% | +195.8% | - |
| Revenue CAGR (3Y) | -4.5% | 0.0% | +26.0% | +121.0% | - | - | - |
| EBITDA CAGR (3Y) | -18.2% | +2.3% | +113.0% | - | - | - | -4.8% |
| Profitability & leverage | |||||||
| Net income margin | +29.8% | +37.0% | +37.0% | +35.2% | +35.2% | +85.2% | -480.0% |
| Return on capital employed | +0.7% | +2.8% | +2.7% | +3.0% | +2.5% | +0.2% | 0.0% |
| Return on net worth | +0.5% | +2.0% | +1.9% | +2.0% | +1.8% | +2.4% | 0.0% |
| Debt / equity | 0.00 | 0.02 | 0.05 | 0.09 | 0.10 | 0.10 | 0.08 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 6.90 | 10.34 | 16.13 | 21.43 | 200.00 | -26.32 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 15.67 | 18.00 | 21.60 | 27.00 | 36.00 | 27.00 | 5.00 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 7.23 | 7.20 | 6.00 | 5.14 | 9.82 | 10.80 | 5.00 |
| EPS (₹) | 0.12 | 0.20 | 0.19 | 0.20 | 0.18 | 0.22 | (0.26) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 36.34 | 9.36 | 9.16 | 8.97 | 8.77 | 8.59 | 8.37 |
To see the full year-wise statements and ratios of Omkar Pharmachem Limited, buy the company report.
Board of directors of Omkar Pharmachem Limited
Omkar Pharmachem has 4 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Parminder Sharma Also directs: Wave Infradevelopers Private Limited, Opportunity Developers Private Limited, Ringold Town Planners Private Limited and 1 more | Director | 14 Nov 2003 | 22 Years 11 Months | Current |
| Bhawani Shankar Goyal | Managing Director | 14 Feb 2020 | 6 Years 8 Months | Current |
| Surjeet Kaur Also directs: A B Sugars Limited, Wave Distilleries and Breweries Limited | Director | 28 Jun 2025 | 1 Years 4 Months | Current |
| Anupam Kumar Mishra | Director | 27 Aug 2025 | 1 Years 2 Months | Current |
Auditor
Omkar Pharmachem Limited is audited by Rajesh J. Shah & Associates for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Rajesh J. Shah & Associates | FY 2022 | 108407W |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 0.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 100.00%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 100.00% | 100.00% | 100.00% | 100.00% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 07 May 1995 | 90111270 | Gujarat State Financial Co-Op | ₹10.89 Lakh | Satisfied |
To see the full charge records of Omkar Pharmachem Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
Omkar Pharmachem Limited has 2 court cases on record: 2 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 0 |
| High courts | 1 | 1 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, GUJARAT | Court case (TAXAP) | Filed against the company by Commissioner of Income Tax- Ahmedabad-Iii | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CS CCC) | Filed against the company by an individual | Disposed |
To see the full case history of Omkar Pharmachem Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Omkar Pharmachem Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Omkar Pharmachem has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACO1845N1ZC | Gujarat | Active | 31 Oct 2020 |
To see the full GST registrations and return filing status of Omkar Pharmachem Limited, buy the company report.
Recent activity
Omkar Pharmachem Limited has 21 board changes on record since 1999: 13 appointments and 8 cessations. The latest: Anupam Kumar Mishra was appointed as Director on 27 Aug 2025.
14 earlier events are in the company report.
Frequently asked questions
Omkar Pharmachem is an active public limited company based in Ahmedabad, Gujarat, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 31 March 1995 (31+ years old) and is registered under CIN L93000GJ1995PLC025276. Listed on BSE: 532167.
Omkar Pharmachem reported revenue of ₹47 Lakh for FY 2025-26 (down 13% YoY) based on standalone financials.
Omkar Pharmachem has 4 current directors:
- Bhawani Shankar Goyal - Managing Director
- Parminder Sharma - Director
- Surjeet Kaur - Director
- Anupam Kumar Mishra - Director
The latest financial statements of Omkar Pharmachem on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 24 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Omkar Pharmachem is 24AAACO1845N1ZC, registered in Gujarat.
The CIN (Corporate Identification Number) of Omkar Pharmachem is L93000GJ1995PLC025276. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Omkar Pharmachem is a listed company as per MCA records. Its shares are listed on BSE (code: 532167).
Omkar Pharmachem has 2 court cases on record: 2 filed against it. Most are in the district courts.
Omkar Pharmachem was incorporated on 31 March 1995, making it 31+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Anupam Kumar Mishra was appointed as Director on 27 Aug 2025. Mamta Pachauri ceased to be Director on 28 Jun 2025. Surjeet Kaur was appointed as Director on 28 Jun 2025. Omkar Pharmachem has 21 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
